-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Atidarsagene Autotemcel in Metachromatic Leukodystrophy (MLD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Atidarsagene Autotemcel in Metachromatic Leukodystrophy (MLD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Atidarsagene Autotemcel in Metachromatic Leukodystrophy (MLD) Drug Details: Atidarsagene autotemcel...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OTL-203 in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome )
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OTL-203 in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OTL-203 in Mucopolysaccharidosis I (MPS I) (Hurler...
-
Product Insights
Thalassemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Thalassemia - Drugs In Development, 2023’, provides an overview of the Thalassemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thalassemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Beta Thalassaemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Beta Thalassaemia - Drugs In Development, 2023’, provides an overview of the Beta Thalassaemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Beta Thalassaemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Primary Immune Deficiency (PID) – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary Immune Deficiency (PID) - Drugs In Development, 2023’, provides an overview of the Primary Immune Deficiency (PID) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Immune Deficiency (PID), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Acquired (Autoimmune) Hemolytic Anemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Acquired (Autoimmune) Hemolytic Anemia - Drugs In Development, 2023’, provides an overview of the Acquired (Autoimmune) Hemolytic Anemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acquired (Autoimmune) Hemolytic Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Frontotemporal Dementia (FTD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Frontotemporal Dementia (FTD) - Drugs In Development, 2023’, provides an overview of the Frontotemporal Dementia (FTD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Frontotemporal Dementia (FTD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...